Patents by Inventor Leonard Zon
Leonard Zon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230277487Abstract: Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.Type: ApplicationFiled: December 26, 2022Publication date: September 7, 2023Inventors: Sahar Tavakoli, Amy J. Wagers, Leonard Zon
-
Patent number: 11534418Abstract: Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.Type: GrantFiled: July 16, 2020Date of Patent: December 27, 2022Assignees: President and Fellows of Harvard College, The Children's Medical Center CorporationInventors: Sahar Tavakoli, Amy J. Wagers, Leonard Zon
-
Publication number: 20200345673Abstract: Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.Type: ApplicationFiled: July 16, 2020Publication date: November 5, 2020Inventors: Sahar Tavakoli, Amy J. Wagers, Leonard Zon
-
Publication number: 20200215038Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: ApplicationFiled: August 27, 2019Publication date: July 9, 2020Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Leonard ZON, Richard M. White
-
Patent number: 10646478Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: GrantFiled: July 6, 2018Date of Patent: May 12, 2020Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTEInventors: Leonard Zon, Richard M. White
-
Publication number: 20190117635Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: ApplicationFiled: July 6, 2018Publication date: April 25, 2019Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTEInventors: Leonard Zon, Richard M. White
-
Publication number: 20190002886Abstract: Described herein are methods, compounds, pharmaceutical compositions, and kits for modulating erythropoiesis by altering occupancy at genomic signaling-centers.Type: ApplicationFiled: June 22, 2018Publication date: January 3, 2019Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard ZON, Avik CHOUDHURI, Eirini TROMPOUKI
-
Patent number: 10016402Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: GrantFiled: June 8, 2015Date of Patent: July 10, 2018Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Leonard Zon, Richard M. White
-
Publication number: 20150328204Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: ApplicationFiled: June 3, 2015Publication date: November 19, 2015Inventors: Leonard Zon, Richard M. White
-
Publication number: 20150306080Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: ApplicationFiled: June 8, 2015Publication date: October 29, 2015Inventors: Leonard Zon, Richard M. White
-
Publication number: 20140031383Abstract: The present invention is directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods herein are directed to screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: ApplicationFiled: February 8, 2012Publication date: January 30, 2014Applicants: DANA-FARBER CANCER INSTITUTE, INC., CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard Zon, Richard M. White
-
Publication number: 20080072337Abstract: The present invention discloses a transgenic zebrafish that express activated BRAF specifically in melanocytes and its uses in screening for agents that can be used to treat melanomas or screening for agents that aggravate or induce melanomas.Type: ApplicationFiled: May 9, 2005Publication date: March 20, 2008Applicant: Children's Medical Center CorporationInventors: Leonard Zon, E. Patton, E. Fisher, Hans Widlund
-
Publication number: 20070218055Abstract: Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in Xenopus oocytes. Human and mouse homologs of the ferroportin1 gene have been identified. The invention includes isolated polynucleotides, vectors and host cells comprising nucleotide sequences encoding Ferroportin1 proteins and variants thereof, including those having iron transport function. The invention also includes polypeptides encoded by ferroportin1 genes and variants of such polypeptides, and fusion polypeptides comprising a Ferroportin1 or a portion thereof.Type: ApplicationFiled: December 19, 2006Publication date: September 20, 2007Inventors: Leonard Zon, Adriana Donovan
-
Publication number: 20050227268Abstract: Methods of expression cloning where a cDNA construct expresses a tagged polypeptide for a biochemical activity of interest are described.Type: ApplicationFiled: February 4, 2005Publication date: October 13, 2005Applicant: Children's Medical Center CorporationInventors: Leonard Zon, Sadhana Agarwal
-
Publication number: 20050221487Abstract: The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a cdx in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous cdx protein to the cell, or by introduction into the cell of a genetic construct encoding a cdx. The cdx is selected from the cdx family and includes cdx1, cdx2, or cdx4. The cdx may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein.Type: ApplicationFiled: September 18, 2003Publication date: October 6, 2005Inventors: Leonard Zon, Alan Davidson, George Daley
-
Publication number: 20050155087Abstract: The present invention is directed to a novel, target-blind approach to drug discovery. The concept is to model human phenotypes in a teleost, such as a zebrafish, and then screen compounds, e.g., small molecules, for their ability to alter the phenotype. Because the screen is performed with a whole vertebrate organism and uses a phenotype as the output, the need to first identify target genes is eliminated. This approach is powerful because a single screen can theoretically detect drugs affecting any target relevant to the phenotype being observed, even if those targets are not yet characterized.Type: ApplicationFiled: December 17, 2002Publication date: July 14, 2005Inventors: Leonard Zon, Howard Stern, Ryan Murphey
-
Patent number: 5700927Abstract: Disclosed is a substantially pure DNA encoding a Tbc1 polypeptide; a substantially pure Tbc1 polypeptide; and methods of using such DNA to express Tbc1 in leukemic stem cells and treat certain leukemias. Also disclosed are methods for diagnosing other leukemias and spermatogenesis disorders by assaying for Tbc1 expression.Type: GrantFiled: December 23, 1994Date of Patent: December 23, 1997Assignee: The Children's Medical Center CorporationInventors: Leonard Zon, Paul Richardson